Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

DrinabantAlso known as AVE1625

Sanofi-Aventis CB1 antagonist; in volunteers it inhibited THC effects from 20 mg, with no effect of its own.

Level of detail

C₂₃H₂₀Cl₂F₂N₂O₂S

CAS 358970-97-5

Family
ECS pharmacological toolAntagonist or inverse agonist
Molar mass
497.40 g/mol

Updated on

In plain terms

Drinabant is a blocker of the CB1 receptor, that is, the opposite of a cannabinoid. In volunteers it reduced several effects of THC from 20 mg, which shows it reaches the brain. No marketing authorisation was found: it remains a study molecule.

Receptors and activity

Target network

CB1AntagonistCentral antagonism in humans: from 20 mg, inhibition of most of the effects of Δ9-THC; no affinity value (Ki or IC50) found (Zuurman et al. 2010)
  • Blocks or inhibits

The lower the cited value, the closer the target sits to Drinabant: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of Drinabant.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1Antagonistno measured value cited

    Central antagonism in humans: from 20 mg, inhibition of most of the effects of Δ9-THC; no affinity value (Ki or IC50) found (Zuurman et al. 2010)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Measured effects

Not characterised. No placebo-controlled human trial has measured the effects of Drinabant, so no level is shown.

Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method

Pharmacology

Drinabant, known by the code AVE1625, is a CB1 receptor antagonist developed by Sanofi-Aventis in the wave of research on this target for obesity, smoking cessation and cognitive impairment (Zuurman et al. 2010). In rats it increased lipolysis, reduced liver glycogen and raised energy expenditure and fat oxidation, independently of reduced food intake (Herling et al. 2007). Zuurman and colleagues used it with Δ9-THC as a probe in volunteers: from 20 mg it inhibited most THC effects, with no effect of its own on psychological or behavioural parameters or heart rate. In rodents, given intraperitoneally (1, 3 and 10 mg/kg), it reversed the abnormally persistent latent inhibition induced by MK-801 or neonatal nitric oxide synthase inhibition and improved working and episodic memory; it did not diminish the efficacy of antipsychotics, reduced the catalepsy and weight gain they cause and, unlike other CB1 antagonists, produced no anxiogenic-like effects (Black et al. 2011). These studies are preclinical or limited to healthy volunteers. According to the trade press, Sanofi ran an oral phase I and II programme, including a phase II trial in cognitive impairment in schizophrenia terminated in 2016 for insufficient efficacy (GEN, 27 December 2018); the licence granted to Opiant at the end of 2018 targeted acute cannabinoid overdose.

History

Source
An entirely synthetic compound with no natural occurrence. It was designed by Sanofi-Aventis as a drug candidate (Herling et al. 2007); no marketing authorisation was found.

Origin

Research tool

No known biological pathway: drinabant is a synthetic compound, an azetidine bearing a bis(4-chlorophenyl)methyl group and a methanesulfonamide function, unrelated to the plant cannabinoid pathway.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Antagonist or inverse agonist

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

Drinabant (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

Common name
Drinabant (AVE1625)
IUPAC name
N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methanesulfonamide
Other names
AVE1625 · drinabantum · AVE-1625

Identifiers

Formula
C₂₃H₂₀Cl₂F₂N₂O₂S
CAS
358970-97-5
InChIKey
IQQBRKLVEALROM-UHFFFAOYSA-N
SMILES
CS(=O)(=O)N(C1CN(C1)C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)C4=CC(=CC(=C4)F)F

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.